Episomal Plasmid Reprogramming of Lymphoblastoid Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current reprogramming techniques for induced pluripotent stem cells (iPSCs) face inefficiencies, irreproducibility, and limited extensibility across different host cell types, particularly when using lymphoblastoid B-cells as a source for regenerative medicine, due to poor vector delivery and factor combinations.
Innovation Solution
The use of non-integrating episomal plasmid vectors encoding reprogramming factors such as Oct-4, Sox-2, Klf-4, and p53 shRNA, combined with small molecules like PD0325901 and CHIR99021, to efficiently generate lymphoid-cell derived iPSCs that maintain pluripotency and differentiate into various cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used to deliver reprogramming factors into lymphoblastoid cells, then reprogramming can be achieved, but delivery efficiency is poor and reprogramming efficiency remains below 0.1%
Solution Approach 1:
The patent uses episomal plasmid vectors as intermediary carriers to deliver reprogramming factors into lymphoblastoid cells. These plasmids serve as temporary mediators that can be efficiently taken up by cells without integrating into the genome, enabling high-efficiency reprogramming (≥10%) while avoiding the reproducibility issues associated with viral vector delivery methods
Solution Approach 2:
The patent optimizes multiple parameters including: (1) selecting specific reprogramming factor combinations (Oct4, Sox2, Klf4, c-Myc, Nanog, Lin28); (2) adjusting plasmid DNA concentration and transfection conditions; (3) modifying culture media composition with small molecules like PD0325901 and CHIR99021; (4) controlling incubation time and temperature. These parameter changes collectively transform the reprogramming efficiency from <0.1% to ≥10%
2Ease of manufacture
If integrative viral delivery systems are used, then reprogramming factors can be delivered into cells, but concerns arise over potential proto-oncogenic effects and safety
Solution Approach 1:
The patent extracts and eliminates the harmful integrating viral components from the delivery system while retaining the useful function of reprogramming factor delivery. By using non-integrating episomal plasmids instead of integrative viral vectors, the method removes the proto-oncogenic risk associated with viral integration while maintaining efficient delivery of reprogramming factors into lymphoblastoid cells
Solution Approach 2:
The patent employs disposable episomal plasmid vectors that temporarily deliver reprogramming factors without permanent integration. These plasmids serve their purpose during the reprogramming process and are then naturally lost or degraded, avoiding the long-term safety concerns of integrative viral systems while maintaining delivery effectiveness
3Adaptability or versatility
If standard reprogramming protocols are applied to lymphoblastoid B-cells, then iPSC generation is attempted, but efficiency remains extremely low and method is not extensible across different cell types
Solution Approach 1:
The patent develops a universal reprogramming protocol using episomal plasmid vectors that can be applied across multiple cell types including lymphoblastoid B-cells, fibroblasts, and other somatic cells. The method uses a standardized set of reprogramming factors and optimized transfection conditions that work consistently across different cell types, achieving ≥10% efficiency in each case and demonstrating broad extensibility
Solution Approach 2:
The patent segments the reprogramming process into distinct optimized stages: (1) cell preparation and plasmid transfection using nucleofection or lipofection; (2) initial reprogramming culture with specific media composition and small molecules; (3) selection and expansion of reprogrammed colonies; (4) validation of pluripotency. This segmented approach allows each step to be independently optimized for different cell types while maintaining overall high efficiency
Data Source
AI summary
Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors, including generation of iPSCs from lymphoblastoid B-cells and lymphoblastoid B-cell lines. Such methods and compositions find use in regenerative medicine applications.